Key Takeaways
- • Worldwide Clinical Trials is acquiring Catalyst Clinical Research for $500 million, with the transaction expected to close in Q1 2026, adding specialized oncology expertise to Worldwide's portfolio.
- • Worldwide, a Research Triangle Park-based full-service CRO with approximately $400 million in annual revenue and 3,500 employees across 60+ countries, strengthens its oncology capabilities through this acquisition of the Wilmington-based Catalyst.
- • Catalyst brings early-phase oncology trial expertise and over 1,000 employees across the U.S., Europe, and Asia-Pacific, positioning the combined entity as a more competitive player in the oncology CRO segment.
- • The deal reflects continued consolidation in the contract research organization sector, with private equity-backed firms pursuing strategic acquisitions to expand therapeutic expertise, service capabilities, and revenue scale.
- • CEO Alistair Macdonald stated the combination "elevates our capabilities in oncology and provides a new solution for our collective customers," signaling intent to cross-sell combined expertise to existing client bases.
Summary
Worldwide Clinical Trials has agreed to acquire Catalyst Clinical Research, a specialized oncology-focused contract research organization, in a $500 million transaction that underscores ongoing consolidation in the pharmaceutical services sector. The deal, which is expected to close in the first quarter of 2026, combines two full-service CROs with complementary therapeutic expertise and geographic reach.
Worldwide Clinical Trials, based in Research Triangle Park, North Carolina, is a mature global CRO with approximately 3,500 employees operating across more than 60 countries. According to the Certified Clinical Research Professionals Society's 2025 directory of the top 50 CROs, Worldwide generated approximately $400 million in annual revenue. The firm maintains broad therapeutic capabilities spanning neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease, while providing services across all phases of clinical research. Recent strategic investments include the opening of a Bioanalytical Center of Excellence and the launch of large molecule services in 2022.
Catalyst Clinical Research, headquartered in Wilmington, North Carolina, is a smaller but specialized player with particular expertise in early-phase oncology trials. The firm operates more than 1,000 employees distributed across the United States, Europe, and the Asia-Pacific region. Its specialized focus on oncology positioned it as an attractive acquisition target despite not meeting the threshold for inclusion in the CCRPS top 50 CROs ranking.
The strategic rationale centers on therapeutic specialization and scale. Worldwide CEO Alistair Macdonald stated that "bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers." This combination enables Worldwide to deepen its oncology offerings while providing Catalyst's specialized expertise access to Worldwide's significantly larger client base and global infrastructure. The transaction exemplifies the broader trend in pharmaceutical services, where private equity-backed CROs pursue acquisitions to add new therapeutic capabilities, expand functional service provider (FSP) offerings, and achieve revenue growth through consolidation.
Worldwide Clinical Trials, based in Research Triangle Park, North Carolina, is a mature global CRO with approximately 3,500 employees operating across more than 60 countries. According to the Certified Clinical Research Professionals Society's 2025 directory of the top 50 CROs, Worldwide generated approximately $400 million in annual revenue. The firm maintains broad therapeutic capabilities spanning neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease, while providing services across all phases of clinical research. Recent strategic investments include the opening of a Bioanalytical Center of Excellence and the launch of large molecule services in 2022.
Catalyst Clinical Research, headquartered in Wilmington, North Carolina, is a smaller but specialized player with particular expertise in early-phase oncology trials. The firm operates more than 1,000 employees distributed across the United States, Europe, and the Asia-Pacific region. Its specialized focus on oncology positioned it as an attractive acquisition target despite not meeting the threshold for inclusion in the CCRPS top 50 CROs ranking.
The strategic rationale centers on therapeutic specialization and scale. Worldwide CEO Alistair Macdonald stated that "bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers." This combination enables Worldwide to deepen its oncology offerings while providing Catalyst's specialized expertise access to Worldwide's significantly larger client base and global infrastructure. The transaction exemplifies the broader trend in pharmaceutical services, where private equity-backed CROs pursue acquisitions to add new therapeutic capabilities, expand functional service provider (FSP) offerings, and achieve revenue growth through consolidation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.